OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
17 feb 2011 - 21:57
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus announces 2010 annual results
Bericht
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), announces today its unaudited annual results for the year ended 31 December 2010.
During 2010, successful clinical Phase IIb results for Locteron® were presented, which further validated the potential of our PolyActive® technology. Jan Egberts joined OctoPlus in November 2010 and formally started as CEO on 1 January 2011. Non-Locteron revenues grew by 18% in the second half-year compared to the first half-year of 2010. In addition, OctoPlus realised a significantly reduced cost base and a successful financing enhanced our cash position.
Datum laatste update: 31 oktober 2025